Abstract
Chimeric antigen receptor (CAR) T-cell therapy has yielded remarkable and durable responses for some patients with relapsed and refractory blood cancers. However, life-threatening toxicities such as immune effector cell-associated neurotoxicity syndrome (ICANS) remain a challenge for broad delivery of such therapies. In this issue, Tang and colleagues demonstrate an association between hypophosphatemia and CAR T cell-induced ICANS. Prospective studies are required to establish if phosphate monitoring is an early predictor for ICANS occurrence and if maintenance of phosphate levels has a role as a preventative strategy.
Original language | English (US) |
---|---|
Pages (from-to) | 1422 |
Number of pages | 1 |
Journal | Cancer Immunology Research |
Volume | 10 |
Issue number | 12 |
DOIs | |
State | Published - 2022 |
ASJC Scopus subject areas
- Immunology
- Cancer Research